Who We Are
Impurities are inevitable. We make them irrelevant. Immunogenicity risk analysis for peptide manufacturing.
Consulting engagements that help CDMOs optimize synthesis, purification, and storage processes to minimize immunogenically concerning impurities. Data-driven process selection beyond traditional purity metrics.
Per-residue immunogenicity analysis of any peptide sequence. Identifies which positions tolerate manufacturing impurities and which are immunogenicity hotspots.
Formal immunogenicity risk assessment reports documenting batch-level impurity screening. Designed to accompany optimized manufacturing processes, providing CDMOs and their downstream clients with audit-ready quality evidence.
Recurring immunogenicity risk assessment across production batches and stability time points. Track process consistency, detect drift, and maintain documented quality evidence over time.
Per-residue immunogenicity risk mapping across the full 31-residue semaglutide sequence. Each position is scored based on how substitution impurities at that site affect immune recognition.
This is a simplified preview. Full sensitivity reports include detailed per-residue analysis, contaminant-specific scoring, and allele-level breakdowns. Contact us to request a complete sample report.
Your existing impurity and analytical data is all we need. No new assays, no additional sample prep, just the batch data you already generate.
The Mint Impurity Risk Index performs in silico immunogenicity analysis using multiple peer-reviewed tools recommended by the Immune Epitope Database.
Each impurity receives a standardized risk classification with documented rationale including affected alleles and actionable risk context.
Formal risk assessment reports suitable for quality files, regulatory inspection, and process optimization decisions. All intermediate data retained for audit purposes.
Interested in immunogenicity risk assessment for your peptide manufacturing process? We'd like to hear from you.
Thank you for reaching out. We'll be in touch shortly.
